1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Ukraine Pharmaceuticals and Healthcare Report Q1 2017

Ukraine Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 83 pages

Includes 3 FREE quarterly updates

BMI View:
While the challenging business environment in Ukraine will continue to pose risks to multinational pharmaceutical firms operating in the country, the much-needed reforms of the healthcare sector are moving closer to realisation. This will significantly boost prospects for drugmakers, where growth potential is considerable given the market's current underdevelopment.

Headline Expenditure Projections
Pharmaceuticals: UAH46.8bn (USD2.13bn) in 2015 to UAH54.0bn (USD2.09bn) in 2016; +15.2% in local currency terms and -2.0% in US dollar terms. Forecast unchanged compared to the previous quarter. Healthcare: UAH113.9bn (USD5.19bn) in 2015 to UAH117.5bn (USD4.55bn) in 2016; 3.2% in local currency terms and -12.3% in US dollar terms. Forecast unchanged compared to the previous quarter. In BMI's Q117 Pharmaceutical Risk/Reward Index, Ukraine is ranked 15th out of the 21 markets in the Central and Eastern European matrix, with a downgraded score of 47.1 compared with the previous quarter (49.5). Ukraine scores considerably below the regional average score of 51.1 in Q117. This decrease is a result of forecast weakness of the hryvnia against the dollar according to BMI's Country Risk team, resulting in a significantly lower sector value growth metric score (measured in USD). The country's continued economic troubles and low per capita medicine expenditure will continue to limit market attractiveness.

Table Of Contents

Ukraine Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Ukraine 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ukraine 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ukraine 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ukraine 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ukraine 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ukraine 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Ukraine 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Ukraine 2012-2020) 22
OTC Drug Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ukraine 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Ukraine 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Ukraine 2014-2020) 27
Industry Risk/Reward Index 28
Central And Eastern Europe Risk/Reward Index - Q1 2017 28
Ukraine Risk/Reward Index 35
Rewards 35
Risks 36
Regulatory Review 37
Intellectual Property Issues 43
Pricing Regime 44
Reimbursement Regime 46
Market Overview 48
Healthcare System 48
Table: Healthcare Resources (Ukraine 2010-2015) 51
Table: Healthcare Personnel (Ukraine 2010-2015) 51
Table: Healthcare Activity (Ukraine 2010-2015) 52
Research And Development 52
Clinical Trials 53
Epidemiology 54
Competitive Landscape 59
Research-Based Industry 59
Table: Association of International Manufacturers (AIPM) Ukraine Members, 2015 60
Table: Multinational Market Activity 61
Generic Drugmakers 62
Pharmaceutical Distribution 64
Pharmaceutical Retail Sector 65
Company Profile 67
Arterium 67
Farmak 70
Demographic Forecast 72
Table: Population Headline Indicators (Ukraine 1990-2025) 73
Table: Key Population Ratios (Ukraine 1990-2025) 73
Table: Urban/Rural Population and Life Expectancy (Ukraine 1990-2025) 74
Table: Population By Age Group (Ukraine 1990-2025) 74
Table: Population By Age Group % (Ukraine 1990-2025) 75
Glossary 77
Methodology 79
Pharmaceutical Expenditure Forecast Model 79
Healthcare Expenditure Forecast Model 79
Notes On Methodology 80
Risk/Reward Index Methodology 81
Index Overview 82
Table: Pharmaceutical Risk/Reward Index Indicators 82
Indicator Weightings 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.